ML033320277

Emergency Plan Implementing Procedures Manual Volume B, Revision 2003-08

ML033320277
Person / Time
Site:	Oconee
Issue date:	11/24/2003
From:	Rosalyn Jones Duke Energy Corp
To:	Document Control Desk, Office of Nuclear Reactor Regulation
References
2003-008
Download: ML033320277 (15)

Text

I Duke R. A. JONES EPower. Vice President A Duke Energy Company Duke Power 29672 / Oconee Nuclear Site 7800 Rochester Highway Seneca, SC 29672 864 885 3158 864 885 3564 fax November 24 2003 U. S. Nuclear Regulatory Commission Document Control Desk Washington, D. C. 20555

Subject:

Oconee Nuclear Station Docket Nos. 50-269, -270, -287 Emergency Plan Implementing Procedures Manual Volume B, Revision 2003-08 Please f ind attached f or your use and review copies of the revision to the Oconee Nuclear Station Emergency Plan:

Volume B Revision 2003-08 November 2003 This revision is being submitted in accordance with 10 CFR 50-54 (q) and does not decrease the effectiveness of the Emergency Plan or the Emergency Plan Implementing Procedures.

Any questions or concerns pertaining to this revision please call Rodney Brown, Emergency Planning Manager at 864-885-3301.

By copy of this letter, two copies of this revision are being provided to the NRC, Region II, Atlanta, Georgia.

Very trul rs, R. A. s VP, Oconee Nuclear Site xc: (w/2 copies of attachments)

Mr. Luis Reyes, Regional Administrator, Region II U. S. Nuclear Regulatory Commission 61 Forsyth St., SW, Suite 24T23 Atlanta, Georgia 30303 w/copy of attachments Mr. James R. Hall Rockville, Maryland (w/o Attachments, Oconee Nuclear Station)

NRC Resident Inspector J. R. Brown, Manager, Emergency Planning DH15' www. duke-energy. corn

November 24, 2003 OCONEE NUCLEAR SITE

SUBJECT:

Emergency Plan Implementing Procedures Volume B, Revision 2003-08 Please make the following changes to the Emergency Plan, Volume B by following the below instructions.

REMOVE INSERT Cover Sheet Rev. 2003-07 Cover Sheet Rev. 2003-08 Table of Contents, page 1 & 2 Table of Contents page 1 & 2 SH/0/B/2005/003, Rev. 000 New Procedure (Tab will be sent later), Insert after RP/0/B/1000/027

DUKE POWER EMERGENCY PLAN IMPLEMENTING PROCEDURES VOLUME B APPROVED:

W. W. Foster, Manager Safety Assurance Date Approved Effective Date VOLUME B REVISION 2003-08 NOVEMBER 2003

VOLUME B TABLE OF CONTENTS Chemistry Lab Determination Of Boron By Manual Colorimetric Titration 11/06/02 LM-O-P003C Chemistry Lab Boron Analysis by Mettler DL 58 Boron Titration 10/28/02 LM-O-P919 CP/l/A/2002/004C Operating Procedure For The Post Accident Liquid Sampling 01/10/03 System (PALSS)

CPI1&21A/2002/005 Post Accident Caustic Injection Into The Low Pressure 09/10/03 Injection System CP/2/A/20021004C Operating Procedure For The Post Accident Liquid Sampling 01/10/03 System (PALSS)

CP/3/A/2002/004C Operation Procedure For The Post-Accident Liquid Sampling 01/10/03 System (PALSS)

CP/3/A/2002/005 Post Accident Caustic Injection Into The Low Pressure 09/10/03 Injection System HIP/O/B/1009/009 Procedure For Determining The Inplant Airborne Radioiodine 12/03/97 Concentration During Accident Conditions HP/0/B11009/012 Distribution Of Potassium Iodide Tablets In The Event Of A 01/09/01 Radioiodine Release L{P/0/B/1009/015 Procedure For Sampling And Quantifying High Level 07/23/01 Gaseous Radioiodine And Particulate Radioactivity HP/O/B/1009/016 Procedure For Emergency Decontamination Of Personnel 12/29/97 And Vehicles On-Site And From Off-Site Remote Assembly Area HP/1/A/1009/017 Operating Procedure For Post-Accident Containment Air 09/13/00 Sampling System HPI2/A/1009/017 Operating Procedure For Post-Accident Containment Air 09/13/00 Sampling System HP/3/A/1009/017 Operating Procedure For Post-Accident Containment Air 09/13/00 Sampling System RPIO/B/100/01 1 Planned Emergency Exposure 02/01/94 RP/OJB/1000/025 Operational Support Center Manager Procedure 04/29/03 RP/O/BI1000/027 Re-Entry Recovery Procedure 05/30/00 I Revision 2003-08 November 2003

VOLUME B TABLE OF CONTENTS SHI0/B/2005/003 Distribution of Potassium Iodide Tablets in the Event of a 11/06/03 Radioiodine Release I Chemistry Manual Emergency Response Guidelines 10/10/03 5.1 Chemistry Manual Post Accident Procedure Use Guidelines 05/29/03 5.2 Maintenance Emergency Preparedness Plan Activation 08/06/02 Directive 9.1 WPG 1.5 Emergency Plan for Work Control Group 03/31/03 OMP 1-7 Operations Emergency Response Organization 08/31/00 Radiation Protection Radiation Protection Emergency Response 09/01/98 Manual 11.1 Radiation Protection Radiation Protection Site Assembly 06/05/00 Manual 11.4 Safety Services Safety Services Emergency Response Procedure 2.1 03/14/00 Procedure 2.1 2 Revision 2003-08 November 2003

(R0401) Duke Power Company (1) ID No. SW/B/2005/003 PROCEDURE PROCESS RECORD Revision No. 000 FOR STANDARD PROCEDURES PREPARATION (2) Procedure

Title:

Distribution of Potassium Iodide Tablets in the Event of a Radiolodine Release (3) Prepared By 91I46PA4JA Q)A& Date 7 /fg)3

. I _t r~~~~~~~~~~

__ 4 (4) Applicable To: ' ONS MNS CNS (5) Technical go t io1 Advisor -df/--_ 4 (6) Requires g Yes El No [A Yes El No IN Yes D NSD 228 ,_ ._

Applicability YES = New procedure or reissue with major changes Determination NO = Reissue with minor changes OR to incorporate previously approved changes (7) Review (QR) By By9 1S.,S, j ',,4 Date A., I Z o3 Date /O/,?1/oy Date_______6__

Cross-Disciplinary By j By £ K r By 1 i#4&

Review (OR) NA Date z4o3 NA Date ?1610, NA Date @

Reactivity Mgmt. By By . By Review (QR) NA CZ Date /a/2i/.3NA NA6/ Date_______

Mgmt. Involvement By By ,, o /_ a By________

Review (Ops. Supt)NA Date %71t oI PNAs/1Date NA4 Date (8) Additional By (QA) By (QA) By (QA)

Reviews Date Date_ Date ByJA t By . By__ _ _

Date 0yZi I Date /1-6 Date_

(9) Approved By ( d\4r By odY/jL Date Date /s li3>3 Date 4'-ZA 3 (10) Use Level Reference Use PERFORMANCE (Compare with Control Copy every 14 calendar days while work is being performed.)

(11) Compared with Control Copy Date Compared with Control Copy Date Compared with Control Copy Date (12) Date(s) Performed Work Order Number (WO#)

COMPLETION (13) Procedure Completion Verification El Yes E NA Check lists or blanks properly initialed, signed, dated, or filled in NA, as appropriate?

El Yes E NA Required enclosures attached?

El Yes E NA Data sheets attached, completed, dated, and signed?

El Yes El NA Charts, graphs, etc., attached and properly dated, identified, and marked?

E Yes E NA Procedure requirements met?

Verified By Date (14) Procedure Completion Approved Date (15) Remarks (attach additional pages, if necessary)

Duke Power Company Procedure No.

Standard Procedure for Oconee, McGuire, and Catawba SwVOB/2005003 Nuclear Stations Revision No.

Distribution of Potassium Iodide Tablets 000 in the Event of a Radioiodine Release Electronic Reference No.

Reference Use SHROOOG _.G

_I__ __ .

SW0/B/2005/003 Page 2 of 5 Distribution of Potassium Iodide Tablets in the Event of a Radioiodine Release

1. Purpose 1.1 This procedure provides information necessary to distribute Active Potassium Iodide (KI) tablets to Emergency Response Organization (ERO) personnel in the event of a release of radioiodine resulting from emergency conditions.

1.2 This procedure also outlines storage and supply information to assure sufficient quality and quantity of thyroid blocking material.

1.3 The level of use for this procedure is "Reference Use".

1.4 This procedure is an Emergency Plan Implementing Procedure (EPIP) for MNS, CNS, and ONS. This procedure must be forwarded to the Emergency Planning Group at each site within 3 working days of approval by the responsible group (PIP 0-93-0701).

2. References 2.1 NCRP Report No. 55; Protection of the Thyroid Gland in the Event of Releases of Radioiodine 1977 2.2 NCRP Report No. 65; Management of Persons Accidentally Contaminated with Radionuclides 1980 2.3 BRH Report; Recommendations of Thyroid Blocking EKI, HITHS Pub. FDA 81-8158 2.4 Radiation Protection Standard Procedure SHlO/B/2001/001, Internal Dose Assessment 2.5 Radiation Protection Policy Manual VI-05, Radiation Accident and Emergency Procedures 2.6 PIP 0-93-701, Distribution of Emergency Plan Procedures 2.7 EPA 400-R-92-001, Manual of Protective Action Guides And Protective Actions For Nuclear Incidents 2.8 Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies, FDA Guidance, November, 2001 2.9 Guidance for Industry, KI in Radiation Emergencies, Questions and Answers, FDA, December, 2002 2.10 Title 10, Code of Federal Regulations, Part 20 (10CFR20)

SH//B/2005/003 Page 3 of 5

3. Limits and Precautions WARNING: Persons who are known to be allergic to KI, iodine, or with pre-existing thyroid disease (e.g., Graves disease, thyroid nodules, Hashimoto's Thyroiditis) shall NOT receive these tablets.

WARNING: Nursing mothers who receive KI tablets shall be advised to use nutrient substitutes (e.g., milk or a formula) for children for the duration of the ten-day tablet use period.

I NOTE: Best results shall be achieved when KI tablets are administered prior to an exposure or immediately after an exposure (within 2 hours2.314815e-5 days <br />5.555556e-4 hours <br />3.306878e-6 weeks <br />7.61e-7 months <br />). Administration as late as 24 hours2.777778e-4 days <br />0.00667 hours <br />3.968254e-5 weeks <br />9.132e-6 months <br /> after the exposure is of less value but still significant enough to justify the administering.

4. Procedure 4.1 Registration of Personnel 4.1.1 The Radiation Protection Manager shall evaluate the distribution of KI for personnel who meet any of the following conditions:

• Personnel suspected of being in an affected area prior to the detection of a radioiodine release

• Personnel known to have been in an affected area

• Personnel who have a need to enter an affected area 4.1.2 Use Enclosure 5.3 to document the actual or expected DAC-hrs of exposure.

NOTE: KI shall be distributed only to prevent a "significant uptake" of radioiodine. A significant uptake is defined as follows:

• That amount of radioiodine taken into the body that would result in a Committed Dose Equivalent (CDE) of 5 rem or more to the thyroid. (Reference 2.8 and 2.9)

• 5 rem CDE to the thyroid is equal to 200 DAC-hrs of iodine exposure. (Reference 2.10) 4.1.3 IF the actual or expected DAC-hrs of exposure is equal to or exceeds 200 DAC-hrs, recommend that the personnel take KI.

SVO/B2005/003 Page 4 of 5 4.1.4 IF determination is made to distribute KI tablets for ingestion by ERO personnel, notify the Emergency Coordinator AND EOF Director of decision.

4.1.5 Complete Enclosure 5.1 for personnel that are to be given KI.

4.1.6 Retain completed procedure in Master File.

4.2 Distribution of Potassium Iodide I NOTE: It is NOT mandatory for any person to take or ingest KI tablets.

4.2.1 Discard any KI bottles that have loose tops.

4.2.2 Discard any KI bottles that are past their expiration date.

4.2.3 Discard any tablets that are disfigured or discolored.

4.2.4 Advise personnel NOT to deviate from the prescribed dosages and dosage rates.

4.2.5 Explain that the prescribed dose is one (1) tablet per day for 10 consecutive days.

4.2.6 Explain that the bottle of KI that the personnel shall be given contains fourteen (14) tablets. The four (4) unused tablets shall be discarded.

4.2.7 Explain that tablets should be taken as close to a 24-hour time period as possible.

4.2.8 Issue one (1) bottle containing fourteen (14) KI tablets to each affected personnel.

4.2.9 Instruct the personnel to ingest the tablet.

4.2.10 Give one (1) package insert to each affected personnel.

4.2.11 Return all unopened KI tablets to the emergency kit.

SHO1/B12005/003 Page 5 of 5 4.3 Internal Dose Assessment Following Radioiodine Exposure NOTE: The maximum iodine concentration in the thyroid is expected to occur approximately 12 hours1.388889e-4 days <br />0.00333 hours <br />1.984127e-5 weeks <br />4.566e-6 months <br /> post-exposure (Reference 2.2).

4.3.1 Schedule all employees receiving KI tablets for a body burden analysis (BBA) approximately 12 hours1.388889e-4 days <br />0.00333 hours <br />1.984127e-5 weeks <br />4.566e-6 months <br /> after the suspected or actual exposure.

4.3.2 Assess the internal dose per Reference 2.4.

4.4 Storage and Supply Requirements for KI Tablets 4.4.1 Replacement KI tablets shall be ordered at least 3 months prior to date of expiration of the current-stock KI tablets.

4.4.2 Upon receiving a shipment of KI, the boxes shall be opened and examined as soon as possible.

4.4.3 Discard any bottles in which the air-tight seal has been broken.

4.4.4 Discard the old KI tablets.

4.4.5 Store the KI tablets in the following manner:

4.4.5.1 Store in an area protected from exposure to light.

4.4.5.2 Store in an area of low humidity.

4.4.5.3 Store in an area where the temperature range is 68 to 77 degrees F.

5. Enclosures 5.1 Potassium Iodide Tablet Distribution Data Sheet 5.2 Package Insert for Thyro-Blockrm Tablets 5.3 DAC-Hour Determination

Enclosure 5.1 Sw/B/2005/003 Potassium Iodide Tablet Distribution Page I of I Data Sheet I have been provided written instruction for the use of Potassium Iodide (KI) tablets. I have read these instructions and intend to use KI in accordance with the manufacturer's instructions. My signature below indicates that I acknowledge that any additional guidance for KI use shall be obtained from a medical authority or the Radiation Protection Manager or designee.

RP Badge Printed Date/Time of Date & Time of Number Name Signature Department Suspected or Initial KI Date/Time Projected Exposure Issuance I . I RP Signature:

Date/Time:_

.) .) )~~~~~~~~~~~~~

Enclosure 5.2 SYOf/B/2005/003 Package Insert for Thyro-BlockT" Tablets Page 1 of 2 Patent Package Insert For THYRO-BLOCKm (POTASSIUM IODIDE)

(pronounced poe-TASS-e-um EYE-oh-dyed)

(abbreviated: KI)

TABLETS U.S.P.

IN A RADIATION EMERGENCY. RADIOACTIVE IODINE COULD BE RELEASED INTO THE AIR.

POTASSIUM IODIDE (A FORM OF IODINE) CAN HELP PROTECT YOU.

IF YOU ARE TOLD TO TAKE THIS MEDICINE, TAKE IT ONE TIME EVERY 24 HOURS. DO NOT TAKE IT MORE OFTEN. MORE WILL NOT HELP YOU AND MAY INCREASE THE RISK OF SIDE EFFECTS. DO NOT TAKE THIS DRUG IF YOU KNOW YOU ARE ALLERGIC TO IODIDE. (SEE SIDE EFFECTS BELOW.)

INDICATIONS THYROID BLOCKING IN A RADIATION EMERGENCY ONLY DIRECTIONS FOR USE Use only as directed by State or local public health authorities in the event of a radiation emergency.

DOSE Tablets: ADULTS AND CHILDREN 1 YEAR OF AGE OR OLDER: One (1) tablet once a day.

Crush for small children.

BABIES UNDER 1 YEAR OF AGE: One-half (1/2) tablet once a day. Crush first.

Take for 10 days unless directed otherwise by State or local public health authorities.

Store at controlled room temperature between 200 and 25 0C (68°- 770F). Keep container tightly closed and protect from light.

WARNING Potassiumiodide should NOT be used by people allergic to iodide.

Keep out of the reach of children. In case of overdose or allergic reaction, contact a physician or the public health authority.

DESCRIPTION Each THYRO-BLOCKm TABLET contains 130mg of potassium iodide.

Other ingredients:

Magnesium stearate, microcrystalline cellulose, silica gel, and sodium thiosulfate

Enclosure 5.2 SH/O/B/2005/003 Package Insert for Thyro-BlockTm Tablets Page 2 of 2 HOW POTASSIUM IODIDE WORKS Certain forms of iodine help your thyroid gland work right. Most people get the iodine they need from foods, like iodized salts or fish. The thyroid can "store" or hold only a certain amount of iodine.

In a radiation emergency, radioactive iodine may be released in the air. This material may be breathed or swallowed. It may enter the thyroid gland and damage it. The damage would probably NOT show itself for years. Children are most likely to have thyroid damage.

IF you take potassium iodide, it will fill-up your thyroid gland. This reduces the chance that harmful radioactive iodine will enter the thyroid gland.

WHO SHOULD NOT TAKE POTASSIUM IODIDE The only people who should NOT take potassium iodide are people who know they are allergic to iodide. You may take potassium iodide even if you are taking medicines for a thyroid problem (for example, a thyroid hormone or antithyroid drug). Pregnant and nursing women and babies and children may also take this drug.

HOW AND WHEN TO TAKE POTASSIUM IODIDE Potassium Iodide should be taken as soon as possible after public health officials tell you. You should take one dose every 24 hours2.777778e-4 days <br />0.00667 hours <br />3.968254e-5 weeks <br />9.132e-6 months <br />. More will NOT help you because the thyroid can "hold" only limited amounts of iodine. Larger doses will increase the risk of side effects. You will probably be told NOT to take the drug for more than 10 days.

SIDE EFFECTS Usually, side effects of potassium iodide happen when people take higher doses for a long time. You should be careful NOT to take more than the recommended dose or take it for longer than you are told. Side effects are unlikely because of the low dose and the short time you will taking the drug.

Possible side effects include skin rashes, swelling of the salivary glands, and "iodism" (metallic taste, burning mouth and throat, sore teeth and gums, symptoms of a head cold, and sometimes stomach upset and diarrhea).

A few people have an allergic reaction with more serious symptoms. These could be fever and joint pains, or swelling of parts of the face and body and at times severe shortness of breath requiring immediate medical attention.

Taking iodide may rarely cause overactivity of the thyroid gland, underactivity of the thyroid gland, or enlargement of the thyroid gland (goiter).

WHAT TO DO IF SIDE EFFECTS OCCUR IF the side effects are severe or if you have an allergic reaction, stop taking potassium iodide. Then, if possible, call a doctor or public health authority for instructions.

HOW SUPPLIED THYRO-BLOCKm TABLETS (Potassium Iodide. U.S.P) are white round tablets, one side scored, other debossed 472 Wallace, each containing 130 mg potassium iodide. Available in bottles of 14 tablets (NDC 0037-0472-20).

WALLACE LABORATORIES Division of CARTER-WALLACE, INC.

Cranbury, New Jersey 08512 IN-0472-04 Rev. 598

Enclosure 5.3 SHI031/2005/003 DAC-Hour Determination Page 1 of 1 Nuclide Conc DAC* Expected DAC (uICUmI) (uCinml) Exposure Hours Time Hrs 1-131 I 2E-8 x I-133 1E-7 x 1-135 7E-7 x Total DAC-Hrs -- L 'liz r-IF total DAC-hrs is 200 or greater, the use of KI is recommended.

RP Signature:

Date/Time:_

• DAC per Reference 2.10